These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19149638)

  • 21. The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon.
    Wise RA; Wigley F; Newball HH; Stevens MB
    Chest; 1982 Jun; 81(6):695-8. PubMed ID: 7075304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma.
    Freedman RR; Girgis R; Mayes MD
    J Rheumatol; 1999 Nov; 26(11):2386-8. PubMed ID: 10555897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local and central orthostatic sympathetic reflexes in Raynaud's phenomenon.
    Engelhart M; Kristensen JK
    Scand J Clin Lab Invest; 1991 Apr; 51(2):191-6. PubMed ID: 2042023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional infrared imaging of paroxysmal ischemic events in patients with Raynaud's phenomenon.
    Grossi G; Mariotti A; Di Donato L; Amerio P; Tulli A; Romani GL; Merla A
    Int J Immunopathol Pharmacol; 2010; 23(2):627-32. PubMed ID: 20646358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon.
    Furspan PB; Chatterjee S; Mayes MD; Freedman RR
    Rheumatology (Oxford); 2005 Apr; 44(4):488-94. PubMed ID: 15695304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent achievements in the management of Raynaud's phenomenon.
    Baumhäkel M; Böhm M
    Vasc Health Risk Manag; 2010 Apr; 6():207-14. PubMed ID: 20407628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of Raynaud's disease.
    Cooke JP; Marshall JM
    Vasc Med; 2005 Nov; 10(4):293-307. PubMed ID: 16444858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
    Maricq HR; Weinrich MC; Valter I; Palesch YY; Maricq JG
    J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Raynaud's phenomenon and vascular disease in systemic sclerosis.
    Generini S; Matucci Cerinic M
    Adv Exp Med Biol; 1999; 455():93-100. PubMed ID: 10599328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
    Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis.
    Goodfield MJ; Rowell NR
    Br J Dermatol; 1988 Nov; 119(5):643-6. PubMed ID: 3207617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Choroidal impairment and macular thinning in patients with systemic sclerosis: the acute study.
    Ingegnoli F; Gualtierotti R; Pierro L; Del Turco C; Miserocchi E; Schioppo T; Meroni PL; ;
    Microvasc Res; 2015 Jan; 97():31-6. PubMed ID: 25262916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma.
    Freedman RR; Girgis R; Mayes MD
    J Rheumatol; 2001 Jan; 28(1):119-21. PubMed ID: 11196511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iontophoretic evaluation of vascular reactivity to acetylcholine in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Marasini B; Conciato L
    Clin Rheumatol; 2001; 20(6):451-2. PubMed ID: 11771535
    [No Abstract]   [Full Text] [Related]  

  • 39. Vasomotor functions of skin microcirculation in vasospastic Raynaud's phenomena.
    Olsen N; Hansen SW
    Acta Physiol Scand Suppl; 1991; 603():101-7. PubMed ID: 1789118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating nerve growth factor in primary and secondary Raynaud's syndrome - results of a pilot study.
    Klein-Weigel P; Gutsche-Petrak B; Humpel C; Riemekasten G; Ivanov S; Heidrich H
    Vasa; 2009 Feb; 38(1):39-45. PubMed ID: 19229802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.